Company profile
Personalised treatment for immune-mediated diseases | PredictImmune
Our technology is the result of over 15 years research and guides personalised treatment of patients with immune-mediated diseases
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
PredictImmune develops prognostic tests immune-mediated diseases, conditions for which a specific cause is currently unknown, such as IBS.
PredictImmune is developing pioneering tools for guiding treatment options in immune-mediated inflammatory diseases with the first product addressing Inflammatory Bowel Disease (both Crohn's disease and ulcerative colitis). The test, based on a simple whole-blood quantitative PCR assay, predicts long-term disease outcome at diagnosis prior to treatment, stratifying patients into those likely to follow either a quiescent or frequently relapsing course and informing clinical management.
Too early.
1 Nov 2018 to 31 Oct 2019
"Immune-mediated diseases, including autoimmune and inflammatory diseases, are common, debilitating and immensely heterogeneous: two patients diagnosed with the same disease may follow markedly different clinical courses. For many autoimmune diseases, effective and often expensive treatments are now available. However, the immunosuppression they induce al...
